FINWIRES · TerminalLIVE
FINWIRES

Voya Financial Supported by Growth Outlook, Capital-Light Model, RBC Says

By

Voya Financial (VOYA) could benefit from its capital-light business, strong free cash flow, organic growth prospects and possible value actions, despite lowered earnings estimates, RBC Capital Markets said in a note Tuesday.

RBC said Voya's Q1 operating EPS of $2.26 beat its $2 estimate and the $2.01 consensus, helped by stronger Employee Benefits earnings, underwriting gains, a stop-loss reserve release and lower expenses; however, net flows were weaker than expected in Retirement and Investment Management, but management still expects positive Retirement flows and more than 2% organic growth in Investment Management.

RBC cut its 2026 and 2027 operating EPS estimates to $9.45 and $10.50 from $9.76 and $10.72, and added that stop-loss remains important for Voya because it helps the company build deeper customer relationships and could be its biggest current opportunity to create shareholder value.

The investment firm said flow improvement could be stronger in H2, while possible reserve releases may support results if claims trends develop favorably.

RBC kept the company's outperform rating and raised its price target to $91 from $87.

Price: $81.48, Change: $+0.52, Percent Change: +0.64%

Related Articles

Wire

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Wire

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Wire

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP